title: Where medicine, business, and public policy intersect.
abstract: Molecular biomarkers are emerging as key indices for the management of patients with cancer and other significant diseases, but their potential has yet to be fully realized. Is there enough collaboration in place to optimize this care revolution?
authors: Chantell L
authors: CL
authors: Wilson
authors: Stephanie
authors: S
authors: Schultz
authors: Scott A
authors: SA
authors: Waldman
references: Nat Biotechnol. 2006 Sep;24(9):1083-90
references: 16964214
references: N Engl J Med. 2004 Dec 30;351(27):2817-26
references: 15591335
references: Science. 2006 May 26;312(5777):1165-8
references: 16728629
references: Science. 2006 Sep 29;313(5795):1853
references: 17008491
references: Science. 2006 Oct 13;314(5797):268-74
references: 16959974
references: Hematol Oncol Clin North Am. 2004 Jun;18(3):657-70, ix-x
references: 15271398
references: N Engl J Med. 2001 Jul 19;345(3):159-64
references: 11463009
references: J Clin Invest. 1998 Feb 15;101(4):847-54
references: 9466980
references: Cancer J. 2004 Sep-Oct;10(5):280-7
references: 15530254
references: Int J Cancer. 2003 Feb 10;103(4):538-43
references: 12478672
references: N Engl J Med. 2004 Dec 23;351(26):2704-14
references: 15616205
references: Blood. 2005 Jan 1;105(1):301-7
references: 15345589
references: Science. 2003 Oct 24;302(5645):588-90
references: 14576416
references: Clin Pharmacol Ther. 2007 Jan;81(1):104-7
references: 17186007
references: Lancet. 2002 Feb 16;359(9306):572-7
references: 11867112
references: Nat Rev Cancer. 2002 Mar;2(3):210-9
references: 11990857
references: Nat Rev Drug Discov. 2006 Nov;5(11):897-902
references: 17080026
references: Ann Intern Med. 2006 Jun 20;144(12):945-8
references: 16785487